At a Glance
  • Status: Active Consortium
  • Year Launched: 2008
  • Initiating Organization: Center for Translational Molecular Medicine (CTMM)
  • Initiator Type: Government
  • Disease focus:
    Type 2 Diabetes
  • Location: Europe



The PREDICCt consortium will combine the latest insights into the causes of Type 2 diabetes mellitus (DM2) with innovative technologies to identify risk-indicators (biomarkers) for DM2 and DM2-related complications, in order to enable (a) stratification of patients at risk of developing diabetes and its cardiovascular complications and (b) development of molecular diagnostics and molecular imaging to identify patients at risk.

Points of Contact

Marten Hofker
Principal Investigator, PREDICCt project
University Medical Center Groningen (UMCG)

Erna Erdtsieck-Ernste
Program Manager, Cardiovascular Disease
phone: +31 (0)40 800 23 06

Sponsors & Partners

BG Medicine NV

Da Vinci Europe Laboratory Solutions


Eindhoven University of Technology


Hycult Biotech

Leiden University Medical Center

Maastricht University Medical Center





Nutricia Research

Oroboros Instruments GmbH

Percuros BV



TNO: Netherlands Organisation for Applied Scientific Research

TOPIC Embedded Systems

University Leiden

University Medical Center Groningen (UMCG)

University Medical Center Utrecht

U-Protein Express BV

Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.